Home » Posts tagged with » sacituzumab govitecan-hziy
Gilead acquisition of Immunomedics : Pharma giant to gain access to breast cancer drug Trodelvy

Gilead acquisition of Immunomedics : Pharma giant to gain access to breast cancer drug Trodelvy

Gilead acquisition of Immunomedics : US pharma giant Gilead Sciences has signed a $21 billion worth deal to acquire New Jersey-based biopharma company Immunomedics to gain access to the latter’s FDA approved breast cancer drug Trodelvy (sacituzumab govitecan-hziy). Immunomedics, which has been offered $88 per share in cash by the US pharma giant, is focused […]